The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Related Research units
Abstract
We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).
Bibliographical data
| Original language | English |
|---|---|
| Article number | 3 |
| ISSN | 0923-7534 |
| Publication status | Published - 2013 |
| pubmed | 23136233 |
|---|
